
1. j infect dis. 2006 apr 1;193(7):987-95. epub 2006 feb 28.

recombinant human erythropoietin prevents death mice cerebral
malaria.

kaiser k(1), texier a, ferrandiz j, buguet a, meiller a, latour c, peyron f,
cespuglio r, picot s.

author information: 
(1)equipe d'accueil 37-32, parasitologie et médicine tropicale, faculté de
médecine, university claude bernard lyon 1, lyon, france.

comment in
    j infect dis. 2007 may 1;195(9):1391; author reply 1391-2.

cerebral involvement malaria complication leads seizure,
coma, death. effect new neuroprotective therapies yet been
investigated, although cerebral malaria shares features neurological
stroke. erythropoietin (epo) one promising drugs area. 
measured effect epo survival mice infected plasmodium
berghei anka demonstrated inoculations recombinant human epo the
beginning clinical manifestations cerebral malaria protect >90% mice
from death. drug effect course parasitemia. effect of
epo related either inhibition apoptosis brain the
regulation increase decrease nitric oxide production brain
and blood, respectively. tumor necrosis factor-alpha interferon-gamma mrna
overexpression inhibited epo, treated mice fewer brain
hemorrhages. epo used patients chronic diseases years, and
more recently used treat acute ischemic stroke. data presented
here provide first evidence indicating cytokine could useful for
the symptomatic prevention mortality acute stage cerebral
malaria.

doi: 10.1086/500844 
pmid: 16518761  [indexed medline]

